202 related articles for article (PubMed ID: 21098757)
1. Analysis of pharmaceutical safety-related regulatory actions in Japan: do tradeoffs exist between safer drugs and launch delay?
Yamada T; Kusama M; Hirai Y; Arnold F; Sugiyama Y; Ono S
Ann Pharmacother; 2010 Dec; 44(12):1976-85. PubMed ID: 21098757
[TBL] [Abstract][Full Text] [Related]
2. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
Ichimaru K; Toyoshima S; Uyama Y
Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
[No Abstract] [Full Text] [Related]
3. Factors associated with spontaneous reporting of adverse drug reactions in Japan.
Yamada T; Watanabe Y; Kusama M; Sugiyama Y; Ono S
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):468-76. PubMed ID: 23172714
[TBL] [Abstract][Full Text] [Related]
4. Hasty approval, more withdrawals.
Prescrire Int; 2005 Aug; 14(78):144. PubMed ID: 16106597
[TBL] [Abstract][Full Text] [Related]
5. Opening Pandora's pillbox: using modern information tools to improve drug safety.
Gottlieb S
Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
[TBL] [Abstract][Full Text] [Related]
6. Safety in numbers--monitoring risk in approved drugs.
Okie S
N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
[No Abstract] [Full Text] [Related]
7. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
8. Benefit-risk assessment: to quantify or not to quantify, that is the question.
Yuan Z; Levitan B; Berlin JA
Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):653-6. PubMed ID: 21538675
[No Abstract] [Full Text] [Related]
9. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization.
O'Neill RT
Stat Med; 1995 May 15-30; 14(9-10):117-27. PubMed ID: 7569506
[TBL] [Abstract][Full Text] [Related]
10. Differences between Japan and the United States in dosages of drugs recently approved in Japan.
Nakashima K; Narukawa M; Kanazu Y; Takeuchi M
J Clin Pharmacol; 2011 Apr; 51(4):549-60. PubMed ID: 20628171
[TBL] [Abstract][Full Text] [Related]
11. Beware of new drugs, study suggests.
Levenson D
Rep Med Guidel Outcomes Res; 2002 May; 13(10):1-2, 5. PubMed ID: 12492085
[No Abstract] [Full Text] [Related]
12. The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.
Danzon PM; Wang YR; Wang L
Health Econ; 2005 Mar; 14(3):269-92. PubMed ID: 15386651
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Safety-Related Regulatory Actions for New Drugs in Japan by Nature of Identified Risks.
Fujikawa M; Ono S
Pharmaceut Med; 2017; 31(5):317-327. PubMed ID: 29056852
[TBL] [Abstract][Full Text] [Related]
14. The challenges of immunogenicity in developing biosimilar products.
Wadhwa M; Thorpe R
IDrugs; 2009 Jul; 12(7):440-4. PubMed ID: 19579165
[TBL] [Abstract][Full Text] [Related]
15. [Participation to international registration trials--from the investigator's standpoint].
Ohtsu A
Gan To Kagaku Ryoho; 2007 Feb; 34(2):297-300. PubMed ID: 17301548
[TBL] [Abstract][Full Text] [Related]
16. The value of drug repositioning in the current pharmaceutical market.
Tobinick EL
Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
[TBL] [Abstract][Full Text] [Related]
17. Drug safety--important to us all!
Böttiger LE
J Intern Med; 2001 Oct; 250(4):269-70. PubMed ID: 11576314
[No Abstract] [Full Text] [Related]
18. Short patent lives jeopardize drug and patient safety.
Hondeghem LM; De Clerck F; Camm J
J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
[TBL] [Abstract][Full Text] [Related]
19. Could conditional release of new drugs provide the information required to study drug effectiveness? - A discussion paper.
Rawson NS; West R; Appel WC
Can J Clin Pharmacol; 2000; 7(4):185-90. PubMed ID: 11118964
[TBL] [Abstract][Full Text] [Related]
20. New drug approval times and clinical evidence in Japan.
Ono S; Yoshioka C; Asaka O; Tamura K; Shibata T; Saito K
Contemp Clin Trials; 2005 Dec; 26(6):660-72. PubMed ID: 16122988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
